WHC.ASX MND.ASX TLX.ASX SEQ.ASX LDX.ASX

Market Roundup: Whitehaven Secures New Facility, Monadelphous Wins Contracts, and Telix Advances PET Agent

Whitehaven Coal Strengthens Funding Position
Whitehaven Coal has secured a new US$600 million syndicated facility, including a US$475 million term loan and a US$125 million revolving credit. This enhances the company's liquidity, extends its debt maturity profile, and reduces its funding cost. The facility will be used to repay a portion of Whitehaven's existing acquisition term loan and replace its existing revolving credit facility. This refinancing further strengthens Whitehaven's capital structure and financial flexibility.

Monadelphous Secures $145 Million in New Contracts
Engineering company Monadelphous Group Limited has announced a series of new contract wins and extensions in the resources sector, valued at approximately $145 million in aggregate. The company has secured a contract with Rio Tinto for a project at the Paraburdoo iron ore mine, as well as two-year extensions to its existing maintenance contracts with BHP and Queensland Alumina. Additionally, Monadelphous has been awarded a contract with Harmony Gold for the construction of a Cyclone Dewatering Plant in Papua New Guinea.

Telix Pharmaceuticals Advances PET Agent for Glioma Imaging
Telix Pharmaceuticals has announced that the U.S. FDA has accepted the company's resubmitted New Drug Application for TLX101-Px (Pixclara), an investigational PET agent for the imaging of glioma (brain cancer). The FDA has assigned a PDUFA goal date of September 11, 2026. TLX101-Px has been granted Orphan Drug and Fast Track designations, and its approval will fulfill a significant unmet medical need for the characterization of recurrent or progressive glioma.

Sequoia Provides Update on InterPrac Disposal
Sequoia Financial Group has provided an update on the proposed disposal of its subsidiary, InterPrac Financial Planning, to Conquest Investment Partners. The Australian Securities and Investments Commission (ASIC) has commenced court proceedings to appoint a receiver over certain property of InterPrac, but Sequoia believes ASIC's concerns are unfounded. Sequoia continues to engage with the ASX regarding the sale and remains committed to progressing the transaction.

Lumos Diagnostics Announces Prospectus Offering
Lumos Diagnostics Holdings Ltd has announced a prospectus offering, including a share purchase plan (SPP) and placement options, to raise up to A$2,000,000 before costs. The company is offering up to 8,888,889 shares at A$0.225 per share, along with 4,444,444 free-attaching new options to eligible shareholders.